After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
MRNA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Moderna Inc is $16.45B. A total of 8.54 million shares were traded on the day, compared to an average of 7.61M shares.
In the most recent transaction, Klinger Shannon Thyme sold 529 shares of MRNA for 44.68 per share on Dec 09 ’24. After the transaction, the Chief Legal Officer now owns 20,446 company shares. In a previous transaction on Dec 09 ’24, Klinger Shannon Thyme bought 529 shares at 44.68 per share.
Among the insiders who sold shares, Klinger Shannon Thyme disposed of 112 shares on Dec 03 ’24 at a per-share price of $43.30. This resulted in the Chief Legal Officer holding 19,837 shares of MRNA after the transaction. In another insider transaction, Hoge Stephen sold 314 shares at $43.30 per share on Dec 03 ’24. Company shares held by the President now total 1,443,904.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MRNA has a high of $170.47 and a low of $35.80.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $30.98, while its Total Shareholder’s Equity was $14.14B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 3.12.
